- July 27, 2021 - Lyndra Therapeutics’ Investigational Oral, Weekly Opioid Use Disorder Treatment LYN-014 Granted Fast Track Designation by FDA
- July 19, 2021 - Lyndra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Lyndra’s Weekly Risperidone (LYN-005) for the Treatment of Adults with Schizophrenia and Other Indications
- June 25, 2021 - Lyndra Therapeutics Presents Preclinical Data on Once-Weekly Oral Buprenorphine Treatment, LYN-013, in Development for Opioid Use Disorder
- June 24, 2021 - Lyndra Therapeutics Completes $60.5 Million Series C Financing
The "Pill of Tomorrow, Here Today"
Currently, medication non-adherence costs more and affects more people than any single disease. Approximately 70% of American adults suffer from at least one chronic disease and ~50% of medications for chronic disease are not taken as prescribed, and hence the U.S. suffers significant associated costs, both in terms of dollars and lives.
These costs are estimated to amount to $100-$289 billion of avoidable spend and more than 125,000+ deaths per year resulting from medication non-adherence.
Lyndra is making daily pills a thing of the past.
Instead of having to take medications daily or more frequently, Lyndra’s oral, ultra-long-acting, sustained-release therapies, could allow patients to take medication weekly, or even monthly. The aim is to improve medication adherence, health outcomes, and help lower the cost of care.
Lyndra’s near-term focus is on addressing health conditions where therapeutic need is largely unmet and where patient non-adherence has been well documented to adversely affect health outcomes. The current pipeline includes therapies for Alzheimer’s disease, HIV, opioid use disorder and schizophrenia as well as a new once-monthly option for oral contraception.
Lyndra is the Only Long-Acting Oral Therapy
The Lyndra Extended Release Oral Capsule is the first ultra-long-acting capsule that lasts a week or longer and can provide a wide range of medicines in a familiar oral capsule form. Once inside the stomach, the capsule delivers steady amounts of medicine for seven days or more. The dosage form has a modular design which provides a unique opportunity to deliver either a single drug or multiple drugs at the same time from just one capsule. The video provides an overview of the dosage form.
Lyndra’s dosage form is a normal capsule containing a drug containing element with components specifically designed to perform certain functions during oral administration, gastric residence and lower GI passage. There is a central “core”, drug-containing “arms” radiating from the core delivering controlled drug release and disintegrating matrices that join the arms to the core. The star-shaped drug containing element folds to fit inside a normal everday capsule for oral administration.
Once inside the stomach, the capsule dissolves, the dosage form unfolds and the drug containing element remains in the stomach and begins to deliver the medicine to the patient. After seven days of remaining in the stomach, the specially designed disintegrating matrices are designed to break down, allowing safe passage through the lower GI tract.
REFERENCES :  https://www.cdc.gov  Rosenbaum, L., Shrank, W. (2013).The NEJM 369(8), 694-695.